Metformin in Parkinson Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
Levodopa Carbidopa: Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
Metformin: Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight.
Study summary
The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum
Eligibility
Primary outcome measure(s)
- change in The Unified Parkinson's Disease Rating Scale (UPDRS). — 6 months
The unified Parkinson's disease rating scale is used to follow the longitudinal course of Parkinson's disease. The UPD rating scale is the most commonly used scale in the clinical study of Parkinson's disease.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Tanta University | Tanta | Egypt | Recruiting |
On this site
📄 Glucophage (metformin) drug profile →More Tanta University trials in Egypt
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07229651 on ClinicalTrials.gov ↗ ← All trials in Egypt